via University of Pennsylvania
In experiments using saliva samples from COVID-19 patients, the gum, which contains the ACE2 protein, neutralized the virus, according to research led by University of Pennsylvania scientists.
A chewing gum laced with a plant-grown protein serves as a “trap” for the SARS-CoV-2 virus, reducing viral load in saliva and potentially tamping down transmission, according to a new study.
The work, led by Henry Daniell at Penn’s School of Dental Medicine and performed in collaboration with scientists at the Perelman School of Medicine and School of Veterinary Medicine, as well as at The Wistar Institute and Fraunhofer USA, could lead to a low-cost tool in the arsenal against the COVID-19 pandemic. Their study was published in the journal Molecular Therapy.
“SARS-CoV-2 replicates in the salivary glands, and we know that when someone who is infected sneezes, coughs, or speaks some of that virus can be expelled and reach others,” says Daniell. “This gum offers an opportunity to neutralize the virus in the saliva, giving us a simple way to possibly cut down on a source of disease transmission.”
Vaccinations for COVID-19 have helped change the course of the pandemic but haven’t stamped out transmission. Even people who are fully vaccinated can still become infected with SARS-CoV-2 and, according to recent research, can carry a viral load similar to those who are unvaccinated.
Prior to the pandemic, Daniell had been studying the angiotensin-converting enzyme 2 (ACE2) protein in the context of treating hypertension. His lab had grown this protein, as well as many others that may have therapeutic potential, using a patented plant-based production system. By bombarding plant material with the DNA of target proteins, they coax plant chloroplasts to take up the DNA and begin growing the proteins. The plant material, freeze-dried and ground-up, could be used as a means of delivering the protein. This system has the potential to avoid the usual obstacles to protein drug synthesis: namely, an expensive production and purification process.
Daniell’s past work on ACE2 proved fortuitous in the context of the COVID-19 pandemic. The receptor for ACE2 on human cells also happens to bind the SARS-CoV-2 spike protein. Other research groups have shown that injections of ACE2 can reduce viral load in people with severe infections.
Meanwhile, another line of work by Daniell and Penn Dental Medicine colleague Hyun (Michel) Koo has involved research to develop a chewing gum infused with plant-grown proteins to disrupt dental plaque. Pairing his insights about ACE2 with this technology, Daniell wondered if such a gum, infused with plant-grown ACE2 proteins, could neutralize SARS-CoV-2 in the oral cavity.
To find out, he reached out to Ronald Collman at Penn Medicine, a virologist and pulmonary and critical care doctor whose team, since the early stages of the pandemic, had been collecting blood, nasal swabs, saliva, and other biospecimens from COVID patients for scientific research.
“Henry contacted me and asked if we had samples to test his approach, what kind of samples would be appropriate to test, and whether we could internally validate the level of SARS-CoV-2 virus in the saliva samples,” Collman says. “That led to a cross-school collaboration building on our microbiome studies.”
To test the chewing gum, the team grew ACE2 in plants, paired with another compound that enables the protein to cross mucosal barriers and facilitates binding, and incorporated the resulting plant material into cinnamon-flavored gum tablets. Incubating samples obtained from nasopharyngeal swabs from COVID-positive patients with the gum, they showed that the ACE2 present could neutralize SARS-CoV-2 viruses.
Those initial investigations were followed by others at The Wistar Institute and Penn Vet, in which viruses, less-pathogenic than SARS-CoV-2, were modified to express the SARS-CoV-2 spike protein. The scientists observed that the gum largely prevented the viruses or viral particles from entering cells, either by blocking the ACE2 receptor on the cells or by binding directly to the spike protein.
Finally, the team exposed saliva samples from COVID-19 patients to the ACE2 gum and found that levels of viral RNA fell so dramatically to be almost undetectable.
The research team is currently working toward obtaining permission to conduct a clinical trial to evaluate whether the approach is safe and effective when tested in people infected with SARS-CoV-2 .
“Henry’s approach of making the proteins in plants and using them orally is inexpensive, hopefully scalable; it really is clever,” Collman says.
Though the research is still in early stages of development, if the clinical trials prove the gum is safe and effective, it could be given to patients whose infection status is unknown or even for a dental check-ups when masks must be removed, to reduce the likelihood of passing the virus to caregivers.
“We are already using masks and other physical barriers to reduce the chance of transmission,” says Daniell. “This gum could be used as an additional tool in that fight.”
Original Article: A chewing gum that could reduce SARS-CoV-2 transmission
More from: University of Pennsylvania | Perelman School of Medicine at the University of Pennsylvania | University of Pennsylvania School of Veterinary Medicine | Wistar Institute | Fraunhofer Society
The Latest on: Reducing SARS-CoV-2 transmission
- SARS-CoV-2 B.1.1.529 (Omicron) Variant Transmission Within Householdson May 26, 2022 at 9:11 pm
According to this report, Omicron infection resulted in high transmission within households, particularly among those who lived with unvaccinated persons or who didn't practice prevention measures.
- Authorized Antibiotic Shows Antiviral Activity Against SARS-CoV-2on May 19, 2022 at 11:00 am
A new research study has explored a large library of authorized drugs to identify compounds that may elicit antiviral activity against SARS-CoV-2. An antibiotic, clofoctol, produced promising results ...
- Reducing COVID Transmission By 20% Could Save 2,000 Australian Lives This Yearon May 19, 2022 at 3:33 am
Australia's COVID death toll is rising, yet public health measures to reduce transmission such as mask mandates are largely a thing of the past.
- Vaccination after SARS-CoV-2 infection linked to a decrease in long COVID symptomson May 18, 2022 at 3:30 pm
CoV-2, the virus responsible for COVID-19, is associated with a decrease in the likelihood of long COVID symptoms, finds a large study of UK adults published by The BMJ today.
- Adding mask recommendation did not significantly reduce the SARS-CoV-2 infection rateon May 14, 2022 at 3:45 am
and no assessment of whether masks could decrease transmission from mask wearers to others. Nevertheless, these study’s findings are significant, as they demonstrate that the recommendation to wear a ...
- Exploring routine saliva testing for SARS-CoV-2 in childrenon May 11, 2022 at 4:15 am
Surveillance remains a critical strategy for reducing the impacts of coronavirus disease 2019 (COVID-19) while the transmission ... Saliva Testing for SARS-CoV-2 in Children: Partnering with ...
- Abbott partners with Indian research firm to study transmission patterns for SARS-CoV-2on May 10, 2022 at 1:18 am
“We are looking at viral evolution and transmission patterns for diseases including HIV, hepatitis, and SARS-CoV-2, especially in ... to help effectively reduce the incidence and spread of ...
- Schools' role in the spread of SARS-CoV-2on May 2, 2022 at 9:53 pm
Therefore, the school-based viral transmission must be curtailed to reduce viral evolution and maintain children's in-person education. The spread of SARS-CoV-2 infections in schools affects not ...
via Bing News
The Latest on: Reducing SARS-CoV-2 transmission
via Google News